Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
139.9 USD | -1.21% | -2.41% | +33.51% |
Jun. 06 | Nuwellis Extends Pilot Program With Dialysis Services Provider DaVita | MT |
May. 24 | FMC, Fresenius and Davita rise after Ozempic news | DP |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- One of the major weak points of the company is its financial situation.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.51% | 12.27B | B- | ||
+24.25% | 88.08B | C+ | ||
-24.01% | 75.32B | B- | ||
+4.23% | 28.19B | C+ | ||
+6.02% | 17.78B | A- | ||
-13.14% | 16.64B | B | ||
+2.09% | 15.64B | A- | ||
+79.55% | 13.81B | C- | ||
+79.66% | 13.26B | C+ | ||
+21.81% | 12.43B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DVA Stock
- Ratings DaVita Inc.